Study of Late-Occurring Complications in Childhood Cancer Survivors
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This clinical trial is studying cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, heart attack, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications.
| Condition | Intervention |
|---|---|
|
Cancer Survivor Cardiovascular Complications Hematopoietic/Lymphoid Cancer Unspecified Childhood Solid Tumor, Protocol Specific |
Other: questionnaire administration Other: laboratory biomarker analysis |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Key Adverse Events After Childhood Cancer |
- Rate of adverse events (cardiac dysfunction, AVN, ischemic stroke, and SMN using a matched case-control) [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]Epidemiological, clinical and laboratory variables will be tested for their association with key adverse events. McNemar's test for paired data will be used to compare the unmatched general characteristics of cases and controls.
- Frequency of mutations or polymorphisms in specific candidate genes in cases and controls [ Time Frame: 1 year ] [ Designated as safety issue: No ]Allele frequencies will be estimated by the gene counting method, and the chi-square test will be used to check for departures from Hardy-Weinberg equilibrium.
Biospecimen Retention: Samples With DNA
peripheral blood or buccal sample
| Estimated Enrollment: | 6900 |
| Study Start Date: | March 2004 |
| Estimated Primary Completion Date: | January 2100 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Observational
DNA from peripheral blood or buccal sample of patients is analyzed for the presence of polymorphisms in candidate genes associated with an increased risk of late-occurring complications, such as cardiac dysfunction (closed to accrual as of 4/17/09), myocardial infarction (closed to accrual as of 6/5/06), ischemic stroke, vascular necrosis (closed to accrual as of 11/26/08), and subsequent malignant neoplasms. Patients also complete a questionnaire detailing family history and health history. |
Other: questionnaire administration
Ancillary studies
Other: laboratory biomarker analysis
Correlative studies
|
Detailed Description:
PRIMARY OBJECTIVES:
I. To identify key adverse events developing in patients (cases) with a primary cancer diagnosed at age 21 or younger.
II. To characterize the key adverse events with respect to the nature of the primary malignancy (pathology, stage) and coded details of the therapeutic protocol.
III. To identify treatment-related and demographic risk factors through a direct comparison of the case-group and controls identified from the remaining patients with the same primary diagnosis.
IV. To compare the frequency of mutations or polymorphisms in specific candidate genes in cases and controls, using constitutional DNA and RNA from the cases and controls.
V. To explore the role and nature of gene-environment interaction in the development of key adverse events.
OUTLINE: This is a multicenter study.
DNA from peripheral blood or buccal sample of patients is analyzed for the presence of polymorphisms in candidate genes associated with an increased risk of late-occurring complications, such as cardiac dysfunction (closed to accrual as of 4/17/09), myocardial infarction (closed to accrual as of 6/5/06), ischemic stroke, avascular necrosis (closed to accrual as of 11/26/08), and subsequent malignant neoplasms.
Patients also complete a questionnaire detailing family history and health history.
Eligibility| Ages Eligible for Study: | up to 21 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
PATIENTS IN ACTIVE FOLLOW-UP WITH KEY ADVERSE EVENTS IDENTIFIED BY COG INSTITUTIONS
Inclusion Criteria:
- Diagnosis of primary cancer at age 21 or younger, irrespective of current age
- No prior history of allogeneic (non-autologous) hematopoietic cell transplant
Development of one of the following key adverse events at any time following initiation of cancer therapy:
- Cardiac dysfunction; Please Note: case enrollment has been closed due to achievement of target accrual
- Ischemic stroke (IS)
- Subsequent malignant neoplasm (SMN)
- Avascular necrosis (AVN); Please Note: case enrollment has been closed due to achievement of target accrual
- Submission of a blood specimen (or in certain cases a buccal cell specimen) to the Clinical Pharmacokinetics Laboratory at St. Jude Children's Research Hospital as per the requirements; Please Note: if a patient is currently receiving active cancer treatment, it is preferable to obtain the blood sample at a time when the patient's WBC is > 2,000
- Written informed consent from the patient and/or the patient's legally authorized guardian, obtained in accordance with institutional policies approved by the U.S. Department of Health and Human Services
- In active follow up by a COG institution; active follow up will be defined as date of last visit or contact by a COG institution within the past 24 months; any type of contact, including contact specifically for participation in ALTE03N1, qualifies as active follow-up; Please Note: treatment on a COG (or legacy group) therapeutic protocol for the primary cancer is NOT required
Contacts and Locations
Show 139 Study Locations| Principal Investigator: | Smita Bhatia | Children's Oncology Group |
More Information
No publications provided
| Responsible Party: | Children's Oncology Group |
| ClinicalTrials.gov Identifier: | NCT00082745 History of Changes |
| Obsolete Identifiers: | NCT00228787 |
| Other Study ID Numbers: | ALTE03N1, NCI-2011-03822, COG-ALTE03N1, CDR0000360708, U10CA095861 |
| Study First Received: | May 14, 2004 |
| Last Updated: | June 10, 2013 |
| Health Authority: | United States: Institutional Review Board |
ClinicalTrials.gov processed this record on June 18, 2013